Business News

Quest Diagnostics Acquires Blueprint Genetics to Broaden Access to Actionable Insights for Genetic and Rare Diseases

SECAUCUS, N.J. and HELSINKI, Finland, Jan. 22, 2020 /PRNewswire/ — Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that it has acquired Blueprint Genetics in an all-cash equity transaction. Blueprint Genetics is a leading specialty genetic testing company with deep expertise in gene variant …

Read More »

BioNTech to Acquire Neon to Strengthen Global Leadership Position in T Cell Therapies

MAINZ, Germany and CAMBRIDGE, Mass., Jan. 16, 2020 (GLOBE NEWSWIRE) — BioNTech (Nasdaq: BNTX, “BioNTech”) and Neon Therapeutics, Inc. (Nasdaq: NTGN, “Neon”) today announced that they have entered into a definitive merger agreement under which BioNTech will acquire Neon in an all-stock transaction valued at approximately $67.0 million. Neon is …

Read More »

Personal Genome Diagnostics and Eisai Partner to Develop Comprehensive Liquid Biopsy Biomarker Discovery Solution

BALTIMORE–(BUSINESS WIRE)–Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, is partnering with Eisai Co., Ltd. to develop a comprehensive liquid biopsy biomarker discovery solution for oncology, to be used by Eisai researchers at their Tsukuba Research Laboratory. The goal of this collaboration is to create a kitted NGS …

Read More »

QIAGEN Builds on Global Collaboration With Amgen for Companion Diagnostic Development in Non-small Cell Lung Cancer

Hilden, Germany and Germantown, Maryland, January 13, 2020 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a strategic collaboration to develop tissue-based companion diagnostics for Amgen’s investigational cancer treatment AMG 510 to identify patients with cancers that have the KRAS G12C mutation. The agreement focuses initially on companion diagnostics …

Read More »

ZebiAI Therapeutics Collaborates with Google Accelerated Science to Unlock Novel Therapeutic Targets

WALTHAM, Mass.–(BUSINESS WIRE)–ZebiAI Therapeutics, Inc., a privately held company, announced a multiyear service and collaboration agreement with Google Accelerated Science (GAS) (https://research.google/teams/applied-science/gas/), Mountain View, CA, focused on the application of machine learning to accelerate the identification of small molecule therapeutics. ZebiAI Therapeutics was established to apply machine learning and DEL …

Read More »

Illumina Announces New Sequencing System, Partnership with Roche and Software Suite to Accelerate Adoption of Genomics

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) further demonstrated its commitment to making genomics more accessible for the potential benefit of patients today with a series of technology and partnership announcements that further the company’s commitment to unlocking the power of the genome. Speaking today at the 38th Annual J.P. Morgan Healthcare …

Read More »

Charles River and Takeda Announce Scientific Collaboration to Identify and Develop Preclinical Candidates

WILMINGTON, Mass.–(BUSINESS WIRE)–Charles River (NYSE: CRL) today announced a multi-year drug discovery collaboration with Takeda Pharmaceutical Company Limited (“Takeda”). Together, Charles River and Takeda will launch multiple integrated programs across Takeda’s four core therapeutic areas—oncology, gastroenterology, neuroscience, and rare disease—with the ultimate goal of delivering preclinical candidates that Takeda can …

Read More »

Biogen Pays $75 Million for Pfizer’s Early-Stage Alzheimer’s Disease Drug Candidate

CAMBRIDGE, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced an agreement to acquire from Pfizer Inc. (NYSE: PFE) PF-05251749, a novel CNS-penetrant small molecule inhibitor of casein kinase 1 (CK1), for the potential treatment of patients with behavioral and neurological symptoms across various psychiatric and …

Read More »

Incyte Pays $750 Million Upfront for Rights to MorphoSys’ Investigational Cancer Drug

MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) and Incyte Corporation (NASDAQ: INCY) announced today that the companies have entered into a collaboration and license agreement to further develop and commercialize MorphoSys’ proprietary anti-CD19 antibody tafasitamab (MOR208) globally. Tafasitamab is an Fc-engineered antibody against CD19 currently …

Read More »

Axsome Enters License Agreement for Pfizer’s Phase 3 Fibromyalgia Candidate

NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, has entered into an agreement with Pfizer Inc. (NYSE: PFE) for an exclusive U.S. license to Pfizer’s clinical and nonclinical data, …

Read More »